Key result
Antioxidant therapies like coenzyme Q10 show promise as supplemental HFpEF treatments by targeting impaired bioenergetics.
Why the study?
Do antioxidants improve outcomes in patients with HFpEF?
Do antioxidants improve outcomes in patients with HFpEF?
This review highlights the pathophysiological role of impaired myocardial bioenergetics and reactive oxygen species in HFpEF, suggesting antioxidants as a potential therapeutic avenue.
Antioxidants should not yet alter HFpEF practice; leaves open efficacy of coenzyme Q10 for targeted trials.
Heart failure with preserved ejection fraction (HFpEF) is a significant cardiovascular condition for more than 50% of patients with heart failure. Currently, there is no effective treatment to decrease morbidity and mortality rates associated with HFpEF because of its pathophysiological heterogeneity. Recent evidence shows that deficiency in myocardial bioenergetics is one of the key pathophysiological factors contributing to diastolic dysfunction in HFpEF. Another known mechanism for HFpEF is an overproduction of free radicals, specifically reactive oxygen species. To reduce free radical formation, antioxidants are often used. This article is a summative review of the recent relevant literature that addresses cardiac bioenergetics, deficiency in myocardial bioenergetics, and increased reactive oxygen species associated with HFpEF and the promising potential use of antioxidants in managing this condition.
No takes yet. Share an insight, caveat, or question.
Hiebert et al. (2016) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Antioxidants (e.g., coenzyme Q10) was evaluated. Antioxidant therapies such as coenzyme Q10 represent a promising potential supplemental treatment for heart failure with preserved ejection fraction by targeting impaired myocardial bioenergetics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: